Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury

S. Okada, Masaya Nakamura, Y. Mikami, Takuya Shimazaki, M. Mihara, Y. Ohsugi, Y. Iwamoto, K. Yoshizaki, T. Kishimoto, Y. Toyama, Hideyuki Okano

研究成果: Article

172 引用 (Scopus)

抄録

Endogenous neural stem/progenitor cells (NSPCs) have recently been shown to differentiate exclusively into astrocytes, the cells that are involved in glial scar formation after spinal cord injury (SCI). The microenvironment of the spinal cord, especially the inflammatory cytokines that dramatically increase in the acute phase at the injury site, is considered to be an important cause of inhibitory mechanism of neuronal differentiation following SCI. Interleukin-6 (IL-6), which has been demonstrated to induce NSPCs to undergo astrocytic differentiation selectively through the JAK/STAT pathway in vitro, has also been demonstrated to play a critical role as a proinflammatory cytokine and to be associated with secondary tissue damage in SCI. In this study, we assessed the efficacy of rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) in the treatment of acute SCI in mice. Immediately after contusive SCI with a modified NYU impactor, mice were intraperitoneally injected with a single dose of MR16-1 (100 μg/g body weight), the lesions were assessed histologically, and the functional recovery was evaluated. MR16-1 not only suppressed the astrocytic diffentiation-promoting effect of IL-6 signaling in vitro but inhibited the development of astrogliosis after SCI in vivo. MR16-1 also decreased the number of invading inflammatory cells and the severity of connective tissue scar formation. In addition, we observed significant functional recovery in the mice treated with MR16-1 compared with control mice. These findings suggest that neutralization of IL-6 signaling in the acute phase of SCI represents an attractive option for the treatment of SCI.

元の言語English
ページ(範囲)265-276
ページ数12
ジャーナルJournal of Neuroscience Research
76
発行部数2
DOI
出版物ステータスPublished - 2004 4 15

Fingerprint

Interleukin-6 Receptors
Spinal Cord Injuries
Interleukin-6
Neural Stem Cells
Cicatrix
Stem Cells
Cytokines
Connective Tissue Cells
Neuroglia
Astrocytes
Spinal Cord
Monoclonal Antibodies
Body Weight
Wounds and Injuries

ASJC Scopus subject areas

  • Neuroscience(all)

これを引用

Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury. / Okada, S.; Nakamura, Masaya; Mikami, Y.; Shimazaki, Takuya; Mihara, M.; Ohsugi, Y.; Iwamoto, Y.; Yoshizaki, K.; Kishimoto, T.; Toyama, Y.; Okano, Hideyuki.

:: Journal of Neuroscience Research, 巻 76, 番号 2, 15.04.2004, p. 265-276.

研究成果: Article

Okada, S. ; Nakamura, Masaya ; Mikami, Y. ; Shimazaki, Takuya ; Mihara, M. ; Ohsugi, Y. ; Iwamoto, Y. ; Yoshizaki, K. ; Kishimoto, T. ; Toyama, Y. ; Okano, Hideyuki. / Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury. :: Journal of Neuroscience Research. 2004 ; 巻 76, 番号 2. pp. 265-276.
@article{56fbd482644b498eaa0054745bd86608,
title = "Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury",
abstract = "Endogenous neural stem/progenitor cells (NSPCs) have recently been shown to differentiate exclusively into astrocytes, the cells that are involved in glial scar formation after spinal cord injury (SCI). The microenvironment of the spinal cord, especially the inflammatory cytokines that dramatically increase in the acute phase at the injury site, is considered to be an important cause of inhibitory mechanism of neuronal differentiation following SCI. Interleukin-6 (IL-6), which has been demonstrated to induce NSPCs to undergo astrocytic differentiation selectively through the JAK/STAT pathway in vitro, has also been demonstrated to play a critical role as a proinflammatory cytokine and to be associated with secondary tissue damage in SCI. In this study, we assessed the efficacy of rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) in the treatment of acute SCI in mice. Immediately after contusive SCI with a modified NYU impactor, mice were intraperitoneally injected with a single dose of MR16-1 (100 μg/g body weight), the lesions were assessed histologically, and the functional recovery was evaluated. MR16-1 not only suppressed the astrocytic diffentiation-promoting effect of IL-6 signaling in vitro but inhibited the development of astrogliosis after SCI in vivo. MR16-1 also decreased the number of invading inflammatory cells and the severity of connective tissue scar formation. In addition, we observed significant functional recovery in the mice treated with MR16-1 compared with control mice. These findings suggest that neutralization of IL-6 signaling in the acute phase of SCI represents an attractive option for the treatment of SCI.",
keywords = "Glial scar, IL-6, Inflammation, Neural stem/progenitor cells, Spinal cord injury",
author = "S. Okada and Masaya Nakamura and Y. Mikami and Takuya Shimazaki and M. Mihara and Y. Ohsugi and Y. Iwamoto and K. Yoshizaki and T. Kishimoto and Y. Toyama and Hideyuki Okano",
year = "2004",
month = "4",
day = "15",
doi = "10.1002/jnr.20044",
language = "English",
volume = "76",
pages = "265--276",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Blockade of Interleukin-6 Receptor Suppresses Reactive Astrogliosis and Ameliorates Functional Recovery in Experimental Spinal Cord Injury

AU - Okada, S.

AU - Nakamura, Masaya

AU - Mikami, Y.

AU - Shimazaki, Takuya

AU - Mihara, M.

AU - Ohsugi, Y.

AU - Iwamoto, Y.

AU - Yoshizaki, K.

AU - Kishimoto, T.

AU - Toyama, Y.

AU - Okano, Hideyuki

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Endogenous neural stem/progenitor cells (NSPCs) have recently been shown to differentiate exclusively into astrocytes, the cells that are involved in glial scar formation after spinal cord injury (SCI). The microenvironment of the spinal cord, especially the inflammatory cytokines that dramatically increase in the acute phase at the injury site, is considered to be an important cause of inhibitory mechanism of neuronal differentiation following SCI. Interleukin-6 (IL-6), which has been demonstrated to induce NSPCs to undergo astrocytic differentiation selectively through the JAK/STAT pathway in vitro, has also been demonstrated to play a critical role as a proinflammatory cytokine and to be associated with secondary tissue damage in SCI. In this study, we assessed the efficacy of rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) in the treatment of acute SCI in mice. Immediately after contusive SCI with a modified NYU impactor, mice were intraperitoneally injected with a single dose of MR16-1 (100 μg/g body weight), the lesions were assessed histologically, and the functional recovery was evaluated. MR16-1 not only suppressed the astrocytic diffentiation-promoting effect of IL-6 signaling in vitro but inhibited the development of astrogliosis after SCI in vivo. MR16-1 also decreased the number of invading inflammatory cells and the severity of connective tissue scar formation. In addition, we observed significant functional recovery in the mice treated with MR16-1 compared with control mice. These findings suggest that neutralization of IL-6 signaling in the acute phase of SCI represents an attractive option for the treatment of SCI.

AB - Endogenous neural stem/progenitor cells (NSPCs) have recently been shown to differentiate exclusively into astrocytes, the cells that are involved in glial scar formation after spinal cord injury (SCI). The microenvironment of the spinal cord, especially the inflammatory cytokines that dramatically increase in the acute phase at the injury site, is considered to be an important cause of inhibitory mechanism of neuronal differentiation following SCI. Interleukin-6 (IL-6), which has been demonstrated to induce NSPCs to undergo astrocytic differentiation selectively through the JAK/STAT pathway in vitro, has also been demonstrated to play a critical role as a proinflammatory cytokine and to be associated with secondary tissue damage in SCI. In this study, we assessed the efficacy of rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) in the treatment of acute SCI in mice. Immediately after contusive SCI with a modified NYU impactor, mice were intraperitoneally injected with a single dose of MR16-1 (100 μg/g body weight), the lesions were assessed histologically, and the functional recovery was evaluated. MR16-1 not only suppressed the astrocytic diffentiation-promoting effect of IL-6 signaling in vitro but inhibited the development of astrogliosis after SCI in vivo. MR16-1 also decreased the number of invading inflammatory cells and the severity of connective tissue scar formation. In addition, we observed significant functional recovery in the mice treated with MR16-1 compared with control mice. These findings suggest that neutralization of IL-6 signaling in the acute phase of SCI represents an attractive option for the treatment of SCI.

KW - Glial scar

KW - IL-6

KW - Inflammation

KW - Neural stem/progenitor cells

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=11144353882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144353882&partnerID=8YFLogxK

U2 - 10.1002/jnr.20044

DO - 10.1002/jnr.20044

M3 - Article

C2 - 15048924

AN - SCOPUS:11144353882

VL - 76

SP - 265

EP - 276

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 2

ER -